Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (2018)

Peer-Reviewed Study · Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, Carducci MA, Sweeney CJ · April 10, 2018

Kyriakopoulos CE et al., 2018-04-10: The long-term CHAARTED analysis reports a 16.8-month median survival gain in high-volume disease (51.2 vs 34.4 months; HR 0.63) and no confirmed benefit in low-volume disease (63.5 months vs not reached; HR 1.04; P=.86), with significant interaction by volume (P=.033).

in the low-volume subgroup, with a median follow-up of 53.8 months, a survival benefit from docetaxel was not confirmed (median OS, 63.5 months for the chemohormonal arm v not reached for the ADT alone arm; HR for death in the combination arm, 1.04; 95% CI, 0.70 to 1.55; P = .86)

Results (PMC HTML, unpaginated)

Kyriakopoulos CE et al., 2018-04-10: The long-term CHAARTED analysis reports a 16.8-month median survival gain in high-volume disease (51.2 vs 34.4 months; HR 0.63) and no confirmed benefit in low-volume disease (63.5 months vs not reached; HR 1.04; P=.86), with significant interaction by volume (P=.033). Funder: NCI/ECOG-ACRIN per the 2015 NEJM report (same trial); Sanofi supplied docetaxel. Conflicts: the JCO disclosure appendix is not rendered in the PMC text – verifier should check the JCO PDF for individual disclosures (several authors report Sanofi advisory roles in this period). Maker: Sanofi. Comparator: ADT alone. Correction: the low-volume HR of 1.04 is a null, not a proven harm, result. Study type: randomized trial.